Medicus Pharma (NASDAQ:MDCX) has marked the one-year anniversary of its Nasdaq listing on Thursday by ringing the opening bell at the Nasdaq MarketSite in New York’s Times Square.
CEO Dr Raza Bokhari said the company was honored with the opportunity, describing the milestone as a reflection of Medicus’ progress since going public and its continued focus on disciplined execution across a streamlined and strategically selected clinical portfolio.
Medicus is focused on advancing key therapeutic assets through Phase 2 proof-of-concept studies while pursuing licensing opportunities and strategic partnerships with established pharmaceutical companies for late-stage development and global commercialization.
The company’s development pipeline is led by two programs. SkinJect is a localized, immunogenic precision therapy in development for the treatment of basal cell carcinoma, the most common form of skin cancer. Medicus estimates the market opportunity for SkinJect at approximately $2 billion.
The pipeline also includes Teverelix, a next-generation gonadotropin-releasing hormone antagonist designed for patients with advanced prostate cancer who are at high cardiovascular risk and susceptible to acute urinary retention relapse. Medicus estimates the combined market opportunity for its pipeline assets at approximately $6 billion.
Medicus noted that the royalty rate payable on worldwide net sales of Teverelix has been reduced from approximately 4% to 2%, with the royalty term clarified on a country-by-country basis in line with standard industry practice. The company said the change improves Teverelix’s profile for future partnering.